18% P<0.0001 REDUCTION of cardiovascular
death or hospitalization for worsening heart failure
26 NNT at 1 year to avoid
one primary end point

SITE SHIFT 02

Ivabradine or placebo on top of guideline-recommended therapy
including ACE inhibitor, β-blocker, mineralocorticoid receptor antagonist.

SITE SHIFT 02

Improvement in all prespecified subgroups

1. Swedberg K, et al. Lancet. 2010;376(9744):875-885.